Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 27, 2026
HeartFlow (HTFL) Stock Jumps +92.9% in 30 Days on Strong Q2 Results

HeartFlow (HTFL) Stock Jumps +92.9% in 30 Days on Strong Q2 Results

Key Takeaways

  • HeartFlow shares rose approximately 92.9% over the trailing 30 days, climbing from about $25.37 to roughly $48.94.
  • The rally was driven by second-quarter 2026 results that beat expectations and a meaningful increase to full-year revenue guidance.
  • Several sell-side firms raised price targets following the report, reinforcing positive sentiment toward the stock.
  • The company remains unprofitable, so growth execution and continued adoption of its Plaque Analysis product remain central to the investment case.

HeartFlow (HTFL) Company Overview and Market Position

HeartFlow, Inc. is a commercial-stage medical technology company based in San Francisco that uses artificial intelligence and advanced computational fluid dynamics to deliver non-invasive solutions for diagnosing and managing coronary artery disease (CAD). Its HeartFlow One platform builds a personalized 3D model of a patient's coronary arteries from a single coronary computed tomography angiography (CCTA) image, and includes Roadmap Analysis, FFRCT Analysis, and Plaque Analysis software. The company has accumulated one of the world's largest databases of annotated cardiac CT images—more than 200 million images—and has helped guide care for over 650,000 patients worldwide. HeartFlow completed its initial public offering in August 2025 and generates the large majority of its revenue in the United States. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

HeartFlow (HTFL) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, HTFL advanced roughly 92.9%, rising from a closing price near $25.37 in late July to about $48.94 by late August. Most of that move occurred in a matter of days after the company reported quarterly results, with shares jumping more than 35% in a single session and continuing to trade near 52-week highs afterward.

The quarterly picture tells a similar but more volatile story. Roughly three months earlier, the stock traded near $28, meaning it has gained on the order of 72% over the period. That broader trend was not linear: shares declined through much of July into the low-to-mid $20s before rebounding sharply once second-quarter results and revised guidance reset investor expectations.

What Drove HTFL Stock Price in the Last 30 Days

The primary catalyst was HeartFlow's second-quarter 2026 earnings report. Revenue rose 48% year over year to approximately $64.1 million, ahead of the consensus estimate near $56.6 million, and adjusted loss per share of $0.07 was narrower than the roughly $0.13 loss analysts had expected. Gross margin reached record levels, expanding to 83.0% on a GAAP basis and 83.3% on a non-GAAP basis.

Management also raised its full-year 2026 revenue guidance to between $246 million and $250 million, up from a prior range of $228 million to $232 million, implying roughly 40% to 42% growth, and lifted its full-year gross margin target. Analysts responded by raising price targets—Stifel moved to $45 from $40 with a Buy rating, JPMorgan raised its target to $45 from $35 with an Overweight rating, and Wells Fargo increased its target to $39 from $37. William Blair's Brandon Vazquez maintained an Outperform rating, noting the guidance increase was roughly twice the size of the earnings beat. From what I see, this level of analyst support adds meaningful weight to the recent move.

What Drove HTFL Stock Performance Over the Last Quarter

Beyond the immediate earnings reaction, the stock's three-month advance reflects a broader narrative of accelerating adoption of AI-enabled cardiac diagnostics. HeartFlow's core FFRCT business has remained durable, while Plaque Analysis has emerged as a fast-growing second revenue engine following expanded reimbursement coverage. The company also launched PCI Navigator, an AI-driven pre-procedure planning tool for interventional cardiologists, and has pointed to a substantially under-penetrated CCTA market as a source of continued growth.

Institutional participation has also increased. According to third-party data, the number of hedge funds holding HeartFlow shares rose from 16 to 25 between consecutive quarters, with combined holdings growing by more than half. At the same time, the stock remains unprofitable, and valuation has expanded alongside the rally, leaving the shares sensitive to any shortfall in adoption or reimbursement trends.

HTFL Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors are likely to focus on the pace of Plaque Analysis adoption, including the company's progress toward its target of roughly 1,200 active sites, and on whether FFRCT case volumes sustain their current growth. Reimbursement developments, new clinical data, and updates to full-year guidance will also matter, as will the company's path toward narrowing operating losses and reaching cash-flow profitability. Because the stock has re-rated sharply, execution against the raised revenue outlook and continued gross-margin expansion will be closely monitored, alongside any signs that adoption is slowing or that valuation has outrun fundamentals. I’m watching this closely as the next few quarters will test whether the momentum holds.

Exploring Tickeron’s Trending AI Robots for Additional Perspective

In my own research process, I occasionally review Tickeron’s Trending AI Robots page to see how automated strategies are performing across various tickers. It offers a focused look at top bots without requiring a full scan of every option available, which can provide a useful complement when evaluating names like this one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HTFL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


HTFL's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for HTFL moved out of overbought territory on September 08, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 instances where the indicator moved out of the overbought zone. In 5 of the 5 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Moving Average Convergence Divergence Histogram (MACD) for HTFL turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 9 similar instances when the indicator turned negative. In 7 of the 9 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HTFL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 18, 2026. You may want to consider a long position or call options on HTFL as a result. In 23 of 23 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The 10-day moving average for HTFL crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

The 50-day moving average for HTFL moved above the 200-day moving average on August 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +5.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where HTFL advanced for three days, in 70 of 77 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

HTFL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 28 of 41 cases where HTFL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HTFL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.773) is normal, around the industry mean (7.474). HTFL has a moderately low P/E Ratio (0.000) as compared to the industry average of (46.724). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.134). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. HTFL's P/S Ratio (19.763) is slightly higher than the industry average of (6.065).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HTFL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 2.86B. The market cap for tickers in the group ranges from 708 to 42.13B. VEEV holds the highest valuation in this group at 42.13B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was 0%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 25%. SDGR experienced the highest price growth at 46%, while CTEV experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was -23% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 74
Price Growth Rating: 52
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
HTFL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Profile
Details
Industry
N/A
Address
331 East Evelyn Avenue
Phone
+1 650 241-1221
Employees
843
Web
https://www.heartflow.com
Interact to see
Advertisement
In a market rattled by geopolitical tension, tariff uncertainty, and Fed rate volatility, one category of stocks continues to electrify traders: penny stocks, microcaps, and small-caps. These sub-$5 shares can surge 50%, 100%, or even 150% in a single session on a news catalyst — but without the right tools, most retail traders get caught on the wrong side. Enter Tickeron's two powerhouse AI robots: the Small-Cap Stocks - AI Trend Trader 60min (FA) and the Penny Stock - MicroCap Signal Bot 60min (FA).
Elite Returns in a Volatile Sector — Both robots delivered annualized returns above 94%, outperforming the vast majority of active semiconductor funds. High Consistency — Win rates of 68–71% mean these robots win more often than they lose — a rare edge in a sector famous for violent swings.
Exceptional Returns: +79.13% annualized return on a starting balance of $8,040.74, demonstrating consistent alpha generation in the comms-tech sector. High Win Rate: 59.43% of trades close in profit, with a Profit Factor of 2.65 — meaning every $1 risked historically returns $2.65.
Tight Risk Management — The 3% TP / 2% SL corridor keeps risk-reward structured and disciplined, cutting losses quickly while locking in gains before reversals. Right Tickers, Right Time — XOM, CVX, and COP are all up roughly 30% year-to-date in 2026, making them among the most high-momentum, liquid energy plays in the market right now.
AngloGold Ashanti (AU) shares are tumbling approximately 11% in premarket trading on March 19, 2026, extending a steep multi-week correction that has now erased more than 35% of the stock's value from its March 2 peak of $129.14. The primary sustained catalyst driving the decline is AngloGold's lowered 2026 production guidance, projecting gold output of 2.80–3.17 million ounces — a mid-point decline versus the company's 2025 output of approximately 3.1 million ounces, and below analyst expectations.
CSIQ shares tumbled approximately 18% in premarket trading on March 19, 2026, following the release of deeply disappointing Q4 2025 earnings before the open. The company reported a net loss of $1.66 per diluted share, far worse than the Wall Street consensus estimate of -$0.98, representing a 69% earnings miss.
YRD shares are tumbling approximately 17% in premarket trading on March 19, 2026, from a prior close of $3.68 to approximately $3.05, following the company's release of Q4 and full-year 2025 financial results before the U.S. market open. Primary catalyst: A dramatic swing to net loss in Q4 2025. Yiren Digital reported a Q4 net loss of RMB 882.2 million (~USD 126.1 million), compared to net income of RMB 331.4 million in Q4 2024 — a more than $250 million deterioration year-over-year.
Shares of MU are down approximately 6.66% in premarket trading on March 19, 2026, sliding from a prior close of $461.73 to around $431.00. Despite a historic earnings beat — fiscal Q2 2026 revenue of $23.86 billion versus the $19.19 billion consensus, and adjusted EPS of $12.20 against an $8.79 estimate — the stock is experiencing a classic "sell the news" reaction.
NEM is trading approximately 9% lower in Thursday premarket, extending Wednesday's 4.56% session loss, as gold prices collapse following the Federal Reserve's hawkish policy hold. Gold spot prices fell 4.21% to $4,616.42 per ounce on March 19, marking the precious metal's sixth straight session of declines — its longest losing streak since late 2024.
Shares of VG are surging approximately +8% in Thursday's premarket session on March 19, 2026, with the stock trading near $16.04, up from the March 18 closing price of $14.85. The primary catalyst is a continuation of bullish momentum driven by a series of analyst price target upgrades, with Scotiabank most recently raising its target from $9 to $11.
LINC shares surged approximately +16% in premarket trading on March 19, 2026, reaching roughly $45.83 from a prior close of $39.51. Primary catalyst: Lincoln Educational Services is hosting its highly anticipated Investor Day today at its brand-new Nashville, TN campus, with presentations beginning at 10:00 am CT (11:00 am ET), live-streamed to investors globally.
PSLV is trading approximately 12% lower in premarket on March 19, 2026, tracking a violent selloff in silver futures. The Federal Reserve's hawkish hold on March 18 — keeping rates at 3.50%–3.75% while signaling fewer cuts ahead — was the primary macro trigger.
The Fed kept rates at 3.5–3.75% and signaled a “higher for longer” stance, with no urgency to cut and a willingness to tighten again if inflation stalls. This backdrop tends to favor quality growth, financials, energy, industrials, and health care, while pressuring long‑duration, leveraged sectors like speculative tech, small caps, utilities, and REITs.
PICS shares fell over 20% today, reversing much of their post‑IPO bounce and dropping well below the US$19 IPO price after initially trading in the mid‑US$15–16 range. The selloff followed PicPay’s Q4 and full‑year 2025 results, which showed strong revenue growth but highlighted thin margins, intense competition and ongoing execution risk in credit underwriting and payments.
RCAT shares fell over 16% today, dropping from recent levels near US$17 toward the mid‑US$14–15 range, after trading as high as US$18.78 in the past year and more than tripling from a 52‑week low of US$4.60.
HYMC shares fell over 13% today, sliding from the mid‑US$30s toward roughly US$31, after trading between US$2.30 and US$58.73 over the past 12 months and closing near US$39 just a few sessions ago.
USAS fell over 10% today, trading around US$5.83 by early afternoon from a previous close of US$6.55 — a one‑day decline of roughly 11% — as more than 5.9 million shares changed hands. The stock had surged earlier in 2026, with some data showing a move from about US$1.11 in March 2025 to over US$7.30 in mid‑March 2026 — a gain of more than 500% — leaving it vulnerable to profit‑taking.
CENX fell about 8.9% today, dropping US$4.94 to US$50.40 by midday, after closing at US$55.34 yesterday; shares now sit roughly 15% below their 52‑week high of US$59.12 but remain far above the 12‑month low of US$13.05. Q4 2025 results showed net sales of US$633.7 million and adjusted net income of US$128.2 million (US$1.25 per share), with adjusted EBITDA of US$170.6 million — a big sequential improvement — but GAAP net income was just US$1.8 million (US$0.02 per share), underscoring earnings volatility.
CNL shares fell over 8% today, trading down from around C$22.90 toward the low‑C$21s, after recently setting a new 1‑year high at C$28.99 on March 2 and gaining more than 70% over the past 12 months.
SMCI shares are plunging approximately 26% in Friday premarket trading, extending sharp after-hours losses from Thursday's session close of $30.79. The primary catalyst is a federal indictment unsealed March 19, 2026, charging three individuals associated with Super Micro — including a company co-founder — with conspiring to illegally export billions of dollars in AI server technology to China.